Chardan Capital Has Lowered Expectations for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Posted by George Bondi on Oct 30th, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its price objective reduced by analysts at Chardan Capital from $425.00 to $375.00 in a note issued to investors on Friday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Chardan Capital‘s target price suggests a potential upside of 127.42% from the stock’s current price.

Other equities analysts have also recently issued reports about the stock. Barclays reduced their price objective on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating on the stock in a research note on Monday, August 3rd. Cantor Fitzgerald reissued a “neutral” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 30th. Sanford C. Bernstein cut Alnylam Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $376.00 to $199.00 in a research note on Friday. Bank of America reiterated a “buy” rating and issued a $287.00 price objective (down from $460.00) on shares of Alnylam Pharmaceuticals in a report on Friday. Finally, Zacks Research lowered Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 23rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $325.39.

Get Our Latest Stock Analysis on Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Stock Performance

ALNY traded down $9.11 during trading on Friday, reaching $164.89. The company’s stock had a trading volume of 6,058,994 shares, compared to its average volume of 1,507,400. The company’s fifty day moving average price is $237.78 and its 200-day moving average price is $287.22. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. The company has a market capitalization of $22.06 billion, a price-to-earnings ratio of 30.65 and a beta of 0.28. Alnylam Pharmaceuticals has a 52-week low of $163.30 and a 52-week high of $479.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.66 by $14.60. The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The firm’s revenue was up 16.7% on a year-over-year basis. During the same period in the previous year, the company earned $2.90 EPS. On average, equities analysts forecast that Alnylam Pharmaceuticals will post 6.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Bryan Supran sold 1,758 shares of the business’s stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the completion of the transaction, the executive vice president directly owned 12,807 shares in the company, valued at $2,905,652.16. The trade was a 12.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP lifted its stake in shares of Alnylam Pharmaceuticals by 9.0% during the 2nd quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company’s stock valued at $635,296,000 after buying an additional 174,482 shares in the last quarter. Legal & General Group Plc bought a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter worth about $278,321,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Alnylam Pharmaceuticals by 7.4% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 727,848 shares of the biopharmaceutical company’s stock valued at $219,104,000 after buying an additional 50,329 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth $148,128,000. Finally, Swiss National Bank grew its stake in Alnylam Pharmaceuticals by 7.9% in the 1st quarter. Swiss National Bank now owns 387,720 shares of the biopharmaceutical company’s stock worth $128,285,000 after acquiring an additional 28,520 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

Positive Sentiment: Alnylam reported third-quarter revenue of approximately $1.46 billion, up 16.7% year over year and above expectations. Adjusted earnings of $16.26 per share also exceeded consensus by a wide margin, although much of the earnings surprise was attributed to a roughly $1.9 billion tax benefit. Alnylam Q3 earnings and revenue beat
Positive Sentiment: The company maintained its fiscal 2026 product-sales outlook and expects $4.2 billion to $4.5 billion in 2026 TTR-related sales. Alnylam also continued advancing its RNAi pipeline, including the nucresiran program. Alnylam TTR sales outlook
Neutral Sentiment: Several analysts lowered their price targets following the results, but most still see potential upside. TD Cowen, Goldman Sachs, RBC and Needham retained positive ratings, while Morgan Stanley and Wells Fargo kept equal-weight ratings. Analyst price-target changes
Negative Sentiment: Investors were concerned about slower U.S. Amvuttra patient starts and decelerating growth in Amvuttra and Onpattro sales. Those trends raised questions about demand and the durability of Alnylam’s core commercial growth. Demand growth concerns
Negative Sentiment: Management acknowledged that execution needs to improve as uncertainty grows around the TTR franchise. The expansion of the TRITON-CM heart-disease trial to roughly 2,250 patients reinforced concerns about development costs, timing and the path toward a potential launch around 2030. Uncertainty around Alnylam’s TTR franchise
Negative Sentiment: Analyst sentiment became more cautious: Bernstein downgraded ALNY to market perform, Stifel cut the stock to hold, and multiple firms reduced price targets. A disclosed law-firm investigation related to an earlier stock-price decline adds another potential overhang. Stifel downgrade

Alnylam Pharmaceuticals Company Profile

(Get Free Report)

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.